These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 27343252)

  • 21. DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition.
    Kerkhofs M; Vervloessem T; Stopa KB; Smith VM; Vogler M; Bultynck G
    Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32708132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies.
    Zhai Y; Tang Q; Fang DD; Deng J; Zhang K; Wang Q; Yin Y; Fu C; Xue SL; Li N; Zhou F; Yang D
    Clin Cancer Res; 2023 Jan; 29(1):183-196. PubMed ID: 36240005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia.
    Imayoshi N; Yoshioka M; Tanaka K; Yang SM; Akahane K; Toda Y; Hosogi S; Inukai T; Okada S; Maloney DJ; Nakahata T; Takita J; Kato I; Ashihara E
    Biochem Biophys Res Commun; 2022 Jan; 590():49-54. PubMed ID: 34971957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
    Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia.
    Urtishak KA; Edwards AY; Wang LS; Hudome A; Robinson BW; Barrett JS; Cao K; Cory L; Moore JS; Bantly AD; Yu QC; Chen IM; Atlas SR; Willman CL; Kundu M; Carroll AJ; Heerema NA; Devidas M; Hilden JM; Dreyer ZE; Hunger SP; Reaman GH; Felix CA
    Blood; 2013 Apr; 121(14):2689-703. PubMed ID: 23393050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of venetoclax for therapy of lymphoid malignancies.
    Zhu H; Almasan A
    Drug Des Devel Ther; 2017; 11():685-694. PubMed ID: 28331288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.
    Ramsey HE; Fischer MA; Lee T; Gorska AE; Arrate MP; Fuller L; Boyd KL; Strickland SA; Sensintaffar J; Hogdal LJ; Ayers GD; Olejniczak ET; Fesik SW; Savona MR
    Cancer Discov; 2018 Dec; 8(12):1566-1581. PubMed ID: 30185627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic targeting of apoptosis in chronic lymphocytic leukemia.
    Ahn IE; Davids MS
    Semin Hematol; 2024 Apr; 61(2):109-118. PubMed ID: 38538512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner.
    Huang S; Li C; Zhang X; Pan J; Li F; Lv Y; Huang J; Ling Q; Ye W; Mao S; Huang X; Jin J
    Mol Oncol; 2020 Oct; 14(10):2560-2573. PubMed ID: 32519423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.
    Guièze R; Liu VM; Rosebrock D; Jourdain AA; Hernández-Sánchez M; Martinez Zurita A; Sun J; Ten Hacken E; Baranowski K; Thompson PA; Heo JM; Cartun Z; Aygün O; Iorgulescu JB; Zhang W; Notarangelo G; Livitz D; Li S; Davids MS; Biran A; Fernandes SM; Brown JR; Lako A; Ciantra ZB; Lawlor MA; Keskin DB; Udeshi ND; Wierda WG; Livak KJ; Letai AG; Neuberg D; Harper JW; Carr SA; Piccioni F; Ott CJ; Leshchiner I; Johannessen CM; Doench J; Mootha VK; Getz G; Wu CJ
    Cancer Cell; 2019 Oct; 36(4):369-384.e13. PubMed ID: 31543463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status.
    Dolnikova A; Kazantsev D; Klanova M; Pokorna E; Sovilj D; Kelemen CD; Tuskova L; Hoferkova E; Mraz M; Helman K; Curik N; Machova Polakova K; Andera L; Trneny M; Klener P
    Blood Adv; 2024 Jul; 8(13):3532-3543. PubMed ID: 38713893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
    Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
    Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.
    Benito JM; Godfrey L; Kojima K; Hogdal L; Wunderlich M; Geng H; Marzo I; Harutyunyan KG; Golfman L; North P; Kerry J; Ballabio E; Chonghaile TN; Gonzalo O; Qiu Y; Jeremias I; Debose L; O'Brien E; Ma H; Zhou P; Jacamo R; Park E; Coombes KR; Zhang N; Thomas DA; O'Brien S; Kantarjian HM; Leverson JD; Kornblau SM; Andreeff M; Müschen M; Zweidler-McKay PA; Mulloy JC; Letai A; Milne TA; Konopleva M
    Cell Rep; 2015 Dec; 13(12):2715-27. PubMed ID: 26711339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevated S100A8/S100A9 expression causes glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia.
    Spijkers-Hagelstein JA; Schneider P; Hulleman E; de Boer J; Williams O; Pieters R; Stam RW
    Leukemia; 2012 Jun; 26(6):1255-65. PubMed ID: 22282267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MLL-Rearranged Acute Lymphoblastic Leukemia.
    El Chaer F; Keng M; Ballen KK
    Curr Hematol Malig Rep; 2020 Apr; 15(2):83-89. PubMed ID: 32350732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.
    Leverson JD; Phillips DC; Mitten MJ; Boghaert ER; Diaz D; Tahir SK; Belmont LD; Nimmer P; Xiao Y; Ma XM; Lowes KN; Kovar P; Chen J; Jin S; Smith M; Xue J; Zhang H; Oleksijew A; Magoc TJ; Vaidya KS; Albert DH; Tarrant JM; La N; Wang L; Tao ZF; Wendt MD; Sampath D; Rosenberg SH; Tse C; Huang DC; Fairbrother WJ; Elmore SW; Souers AJ
    Sci Transl Med; 2015 Mar; 7(279):279ra40. PubMed ID: 25787766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.
    Teh TC; Nguyen NY; Moujalled DM; Segal D; Pomilio G; Rijal S; Jabbour A; Cummins K; Lackovic K; Blombery P; Thompson E; Ekert PG; Lessene G; Glaser SP; Huang DCS; Roberts AW; Guthridge MA; Wei AH
    Leukemia; 2018 Feb; 32(2):303-312. PubMed ID: 28751770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199.
    Khaw SL; Mérino D; Anderson MA; Glaser SP; Bouillet P; Roberts AW; Huang DC
    Leukemia; 2014 Jun; 28(6):1207-15. PubMed ID: 24402163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.
    He Y; Koch R; Budamagunta V; Zhang P; Zhang X; Khan S; Thummuri D; Ortiz YT; Zhang X; Lv D; Wiegand JS; Li W; Palmer AC; Zheng G; Weinstock DM; Zhou D
    J Hematol Oncol; 2020 Jul; 13(1):95. PubMed ID: 32677976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
    Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.